Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraoral Administration of Onabotulinum Toxin A for Continuous Neuropathic Pain
NCT03848143Phase 2Completed
- Start
- Sep 2019
- Primary completion
- Jun 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of onabotulinumtoxinA in neuropathic pain. Primary endpoint: Change in Pain Intensity at 6 months. Started Sep 2019; status: completed.
02
Drugs
onabotulinumtoxinA
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT03848143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03848143.